23.39
0.26%
-0.06
After Hours:
23.39
Atricure Inc stock is currently priced at $23.39, with a 24-hour trading volume of 967.04K.
It has seen a -0.26% decreased in the last 24 hours and a -26.77% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $23.53 pivot point. If it approaches the $23.05 support level, significant changes may occur.
Atricure Inc Stock (ATRC) Financials Data
Atricure Inc (ATRC) Revenue 2024
ATRC reported a revenue (TTM) of $399.25 million for the quarter ending December 31, 2023, a +20.84% rise year-over-year.
Atricure Inc (ATRC) Net Income 2024
ATRC net income (TTM) was -$30.44 million for the quarter ending December 31, 2023, a +34.49% increase year-over-year.
Atricure Inc (ATRC) Cash Flow 2024
ATRC recorded a free cash flow (TTM) of -$37.51 million for the quarter ending December 31, 2023, a +3.86% increase year-over-year.
Atricure Inc (ATRC) Earnings per Share 2024
ATRC earnings per share (TTM) was -$0.66 for the quarter ending December 31, 2023, a +34.65% growth year-over-year.
Atricure Inc Stock (ATRC) Latest News
Key Takeaways From AtriCure Analyst Ratings
Benzinga
Coinbase To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Friday
Benzinga
Cracking The Code: Understanding Analyst Reviews For AtriCure
Benzinga
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings
Zacks Investment Research
AtriCure (ATRC) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Seeking Clues to AtriCure (ATRC) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Zacks Investment Research
About Atricure Inc
AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. AtriCure sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.
Cap:
|
Volume (24h):